SORRENTO THERAPEUTICS

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch SRNE and buy or sell other stocks, ETFs, and their options commission-free!

About SRNE

Sorrento Therapeutics, Inc. engages in the research, development, and manufacture of biopharmaceutical products. It operates through the Sorrento Therapeutics and Scilex segments. 

CEO
Henry H. Ji, PhD
CEOHenry H. Ji, PhD
Employees
Employees
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1989
Founded1989
Employees
Employees

SRNE Key Statistics

Market cap
303.20K
Market cap303.20K
Price-Earnings ratio
Price-Earnings ratio
Dividend yield
Dividend yield
Average volume
172.54K
Average volume172.54K
High today
$0.0006
High today$0.0006
Low today
$0.0005
Low today$0.0005
Open price
$0.0006
Open price$0.0006
Volume
1.00K
Volume1.00K
52 Week high
$0.0985
52 Week high$0.0985
52 Week low
52 Week low

Stock Snapshot

The current SORRENTO THERAPEUTICS(SRNE) stock price is $0.00, with a market capitalization of 303.2K.

During the trading session on 2026-07-03, SORRENTO THERAPEUTICS(SRNE) shares reached a daily high of $0.00 and a low of $0.00. At a current price of $0.00, the stock is +20.0% higher than the low and still 0.0% under the high.

Trading volume for SORRENTO THERAPEUTICS(SRNE) stock has reached 1K, versus its average volume of 172.54K.

People also own

Based on the portfolios of people who own SRNE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.